Scientific Review & AQP Support
A dedicated outsourced service for scientific accuracy, reference verification, and evidence-to-claim alignment—so materials are signatory-ready before final approval.
- Outsourced capacity • Fast turnaround • Clear decision trail
Reference checking: accuracy, completeness, traceability
Claim substantiation: evidence supports wording, context, and balance
Data integrity: numbers, endpoints, population, study design, limitations
Consistency checks across assets (core claims, tables, footnotes)
Clear outputs: Approved / Approved with changes / Not supportable
What you’ll achieve
Reduce rework and risk by fixing scientific issues before they hit final signatory.
- Fewer approval cycles with cleaner drafts and fewer “last-minute” issues
- Stronger, defensible claims aligned to the evidence base
- Reduced compliance risk from mis-citation, overreach, or missing context
- Audit-friendly reference trail and consistent claim standards
What’s included in the outsourced scientific check
This is a defined, repeatable service—designed to plug into your MLR/approval workflow.
Reference verification (end-to-end): correct source, correct details, correct citation format
Quote/number checking: data points match the source (tables, graphs, footnotes)
Claim substantiation: claim is supported, appropriately qualified, and not overstated
Evidence context: study design, population, endpoints, duration, limitations reflected accurately
Consistency review: same claim phrasing, numbers, and references across the pack
Scientific clarity edits (light-touch): tighten ambiguous or scientifically risky phrasing
Out of scope (so it’s clear): This service is not final ABPI signatory sign-off. It is the scientific/AQP layer that makes materials signatory-ready.
How it works
A simple outsourced workflow that improves quality without slowing delivery.
You send the asset + references. We return a marked-up version, a clean evidence trail, and a clear “supportability” status.
Intake + triage (what you send)
Send the draft asset(s), claim list (if you have one), and the supporting references (PDFs or links). We confirm scope, complexity, and turnaround—then begin review.
• Asset (PPT/PDF/Word) + claim list (optional)
• Supporting references (PDFs/links)
• Intended audience/channel (optional but helpful)
Deliverables & turnaround
Turnaround is agreed based on volume and complexity. Expedited pathways are available for priority items (e.g., congress or launch).
• Marked-up file with tracked changes / comments
• Reference verification log (missing/incorrect/outdated citations flagged)
• Claim support status: Supported / Needs qualification / Not supported
• Optional: Claims & Substantiation Table (signatory-ready)
Typical use cases
Job bag packs needing a fast scientific quality lift
Congress slide decks and symposium materials
Website/landing page claims and downloadable PDFs
Campaign packs where consistency across assets matters
Materials with comparatives, superlatives, or “edge-case” scientific framing
Or: Just simply need more support whilst awaiting recruitment needs
FAQ
Frequently Asked Questions
It’s structured checking of references, data accuracy, and evidence-to-claim alignment—so the wording, numbers, and context are scientifically defensible and consistent across the material.
No. This is the scientific/AQP support layer that strengthens materials before final signatory review. It reduces rework and improves the quality of what reaches sign-off.
Each week you’ll get a short learning module plus a supporting podcast, followed by a live session to apply it to practical scenarios and real-world patterns from completed PMCPA cases. Most teams find the learning is immediately usable in current job bags.
It’s a clear supportability status for each key claim based on the references provided. “Needs qualification” means the claim can work but must be framed more accurately (population, endpoint, limitations, magnitude, etc.).
Yes—optional. If you want a signatory-ready pack, I can return a structured claims & substantiation table alongside the marked-up asset.
Yes. I can align outputs to your preferred formats (claim tables, referencing style, evidence logs) so it drops into your workflow.
The asset file, the references (PDFs/links), and (if available) your intended audience/channel and any key claims you want checked first.
Yes—by agreement. For urgent items (congress/launch), we can prioritise the highest-risk claims first and complete the remainder to an agreed plan.
Either. One-off packs are fine, or we can set up an ongoing outsourced support model for predictable capacity and turnaround.
Insights and More
News & PMCPA Cases

AI-Enabled MLR in Pharma: Governance First Guide
AI tools can enhance Medical affairs MLR workflows but pose governance challenges. It’s crucial to implement strict controls, maintain compliance with the ABPI Code, and ensure documented human oversight.
AstraZeneca: promotional meeting misclassified and LinkedIn ‘likes/reposts’ led to pre-authorisation promotion and public advertising concerns (AUTH/3729/1/23)
Six complaints against AstraZeneca. Breaches found for a UK meeting treated as non-promotional (certification/PI and ‘cure’ claims) and for LinkedIn engagement promoting an unlicensed medicine and a POM to the public.

Blurred boundaries: Lessons from the Eli Lilly Facebook Breast Cancer Ad (CASE/3869/12/23)
TL;DR: Even a globally reputable company using trusted partners can stumble into serious compliance breaches online. All pharma professionals should be proactive, transparent, and vigilant—especially with third-party digital campaigns. The future of ethical pharmaceutical advertising depends on it. For many in pharma, the digital landscape can feel like quicksand—seemingly solid

The ripple effect of a single click: What Moderna’s mRESVIA PMCPA case really teaches us
Ever wondered how something as innocent as a LinkedIn ‘like’ could pull an entire pharma company into PMCPA hot water? I once underestimated how quickly a digital echo can travel, but the Moderna mRESVIA PMCPA case showed the true power (and risk) of our online footprint. Let’s break down what

LinkedIn landmines: The hidden pitfalls of pharma social media
What 214 Social Media cases taught me about compliance risk I’ve just finished reviewing 214 PMCPA cases where social media played a role. The pattern is undeniable: LinkedIn and other platforms are now a leading source of ABPI Code breaches. And the worrying part? Most of these breaches started with

Beyond the headlines: What the Epidyolex Press Release ruling really teaches pharma teams
Let me take you behind the scenes of a Jazz Pharmaceuticals case that could have happened to any of us. In my early years as a final signatory I found myself agonising over whether mentioning a drug’s brand name too many times in a Press Release could result in a
